Insider trades
Open-market buys and sales that US company officers, directors and 10% owners file, newest filing first.
| Trade type | ||||||||
|---|---|---|---|---|---|---|---|---|
Sandra MilliganDirector | Gossamer BioGOSS | Open-market buy | 25/08/19 | 25/08/20 | 26,050 sh | $1.92 | $50,016 | +81.4% |
Richard ArandaChief Medical Officer | Gossamer BioGOSS | Open-market sale | 24/06/24 | 24/06/25 | 1,908 sh | $0.66 | $1,259.28 | −1.0% |
Faheem HasnainPresident & CEO | Gossamer BioGOSS | Open-market buy | 24/06/21 | 24/06/24 | 372,000 sh | $0.67 | $249,240 | +7.4% |
Bryan GiraudoCOO/CFO | Gossamer BioGOSS | Open-market buy | 24/06/18 | 24/06/20 | 100,000 sh | $0.59 | $59,000 | +26.3% |
Robert Paul Smith Jr.Chief Commercial Officer | Gossamer BioGOSS | Open-market buy | 24/06/17 | 24/06/20 | 25,000 sh | $0.60 | $15,000 | No record |
Faheem HasnainPresident & CEO | Gossamer BioGOSS | Open-market sale | 24/03/27 | 24/03/28 | 23,172 sh | $1.16 | $26,879.52 | −16.2% |
Waage ChristianEVP, Tech Ops and Admin | Gossamer BioGOSS | Open-market sale | 24/03/27 | 24/03/28 | 6,430 sh | $1.16 | $7,458.8 | −1.1% |
Bryan GiraudoCOO/CFO | Gossamer BioGOSS | Open-market sale | 24/03/27 | 24/03/28 | 6,430 sh | $1.16 | $7,458.8 | −6.5% |
Caryn PetersonEVP, Regulatory Affairs | Gossamer BioGOSS | Open-market sale | 24/03/18 | 24/03/19 | 4,018 sh | $1.33 | $5,343.94 | −7.5% |
Richard ArandaChief Medical Officer | Gossamer BioGOSS | Open-market sale | 24/03/18 | 24/03/19 | 4,018 sh | $1.33 | $5,343.94 | −2.0% |
Sandra MilliganDirector | Gossamer BioGOSS | Open-market buy | 23/11/15 | 23/11/17 | 32,000 sh | $0.79 | $25,280 | No record |
Bryan GiraudoCOO/CFO | Gossamer BioGOSS | Open-market buy | 23/11/13 | 23/11/14 | 200,000 sh | $0.56 | $112,000 | +111.1% |
Richard ArandaChief Medical Officer | Gossamer BioGOSS | Open-market sale | 23/06/22 | 23/06/26 | 1,814 sh | $1.29 | $2,340.06 | −0.9% |
Bryan GiraudoCOO/CFO | Gossamer BioGOSS | Open-market buy | 23/04/04 | 23/04/05 | 55,000 sh | $1.02 | $56,100 | +77.5% |
Gossamer BioGOSS | Open-market buy | 23/03/20–23/03/22 | 23/03/22 | 878,572 sh3 trades | $1.14avg. | $999,180.29 | +24.3% | |
Waage ChristianEVP, Tech Ops and Admin | Gossamer BioGOSS | Open-market buy | 23/03/20 | 23/03/22 | 18,500 sh | $1.20 | $22,200 | +133.2% |
Bryan GiraudoCOO/CFO | Gossamer BioGOSS | Open-market buy | 23/03/20 | 23/03/22 | 50,000 sh | $0.97 | $48,500 | +238.2% |
Caryn PetersonEVP, Regulatory Affairs | Gossamer BioGOSS | Open-market sale | 23/03/16 | 23/03/20 | 7,564 sh | $1.10 | $8,320.4 | −12.3% |
Laura CarterChief Scientific Officer | Gossamer BioGOSS | Open-market sale | 23/03/16 | 23/03/20 | 6,029 sh | $1.10 | $6,631.9 | −7.3% |
Richard ArandaChief Medical Officer | Gossamer BioGOSS | Open-market sale | 23/03/16 | 23/03/20 | 7,563 sh | $1.10 | $8,319.3 | −3.7% |
